MIRA PHARMACEUTICALS, INC. (MIRA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
MIRA PHARMACEUTICALS, INC. (MIRA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Consulting Agreement This Consulting Agreement (this “Agreement”) is entered into as of June 6, 2026 (“Effective Date”) by and between MIRA Pharmaceuticals, Inc. (“Company”), and Andriy Mushak (“Consultant”). Company and Consultant may be
How this was made
The 30-second read
Why it matters
This is a governance/finance-operations update that may affect execution quality for SEC reporting and audit processes, but it does not disclose new financial results, guidance, or a transaction.
Market read
Traders may monitor for follow-on disclosures (e.g., audit/internal control updates, financing activity, or further officer changes), but the current filing alone is not a direct fundamental catalyst.
What to watch
The agreement’s scope (SEC filings, audit readiness, internal controls, capital-markets support) could matter if MIRA is preparing for a near-term financing or major regulatory milestone, but the filing provides no such event details.
Background
The SEC 8-K (Item 5.02) attaches an exhibit for a June 6, 2026 consulting agreement appointing a fractional CFO to oversee SEC compliance, audit readiness, internal controls, and capital-markets support.
Ticker impact
MIRA filed an 8-K disclosing a consulting agreement appointing a fractional CFO and setting $6,000/month compensation terms.
Low-to-moderate, likely limited unless investors interpret the move as a response to reporting, audit, or financing needs.
The filing is a corporate governance/finance operations change (fractional CFO) with defined compensation, but it does not include earnings, guidance, financing, or regulatory outcomes.
Market effects
Minimal; fractional CFO/SEC reporting oversight is company-specific and not a sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Investors may view the fractional CFO appointment as cost-control and improved SEC/audit readiness rather than distress.
Key entities
- issuerMIRA Pharmaceuticals, Inc.
Company filing the 8-K and entering the fractional CFO consulting agreement.
- consultantAndriy Mushak
Named consultant providing fractional CFO services under the agreement.
